WO2006020277A3 - Acylated piperidine derivatives as melanocortin-4 receptor agonists - Google Patents

Acylated piperidine derivatives as melanocortin-4 receptor agonists Download PDF

Info

Publication number
WO2006020277A3
WO2006020277A3 PCT/US2005/025505 US2005025505W WO2006020277A3 WO 2006020277 A3 WO2006020277 A3 WO 2006020277A3 US 2005025505 W US2005025505 W US 2005025505W WO 2006020277 A3 WO2006020277 A3 WO 2006020277A3
Authority
WO
WIPO (PCT)
Prior art keywords
melanocortin
piperidine derivatives
receptor agonists
acylated piperidine
receptor
Prior art date
Application number
PCT/US2005/025505
Other languages
French (fr)
Other versions
WO2006020277A2 (en
Inventor
Raman K Bakshi
James P Dellureficio
Ravi P Nargund
Original Assignee
Merck & Co Inc
Raman K Bakshi
James P Dellureficio
Ravi P Nargund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, Raman K Bakshi, James P Dellureficio, Ravi P Nargund filed Critical Merck & Co Inc
Priority to AU2005274701A priority Critical patent/AU2005274701A1/en
Priority to JP2007522636A priority patent/JP2008506779A/en
Priority to AT05773009T priority patent/ATE454148T1/en
Priority to DE602005018779T priority patent/DE602005018779D1/en
Priority to EP05773009A priority patent/EP1773338B1/en
Priority to CA002574156A priority patent/CA2574156A1/en
Priority to US11/632,000 priority patent/US7618987B2/en
Publication of WO2006020277A2 publication Critical patent/WO2006020277A2/en
Publication of WO2006020277A3 publication Critical patent/WO2006020277A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Certain novel N-acylated piperidine derivatives are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.
PCT/US2005/025505 2004-07-19 2005-07-15 Acylated piperidine derivatives as melanocortin-4 receptor agonists WO2006020277A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2005274701A AU2005274701A1 (en) 2004-07-19 2005-07-15 Acylated piperidine derivatives as melanocortin-4 receptor agonists
JP2007522636A JP2008506779A (en) 2004-07-19 2005-07-15 Acylated piperidine derivatives as agonists of melanocortin-4 receptor
AT05773009T ATE454148T1 (en) 2004-07-19 2005-07-15 ACYLATED PIPERIDED DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS
DE602005018779T DE602005018779D1 (en) 2004-07-19 2005-07-15 ACYLATED PIPERIDINE DERIVATIVES THAN MELANOCORTIN-4-RECEPTOR AGONISTS
EP05773009A EP1773338B1 (en) 2004-07-19 2005-07-15 Acylated piperidine derivatives as melanocortin-4 receptor agonists
CA002574156A CA2574156A1 (en) 2004-07-19 2005-07-15 Acylated piperidine derivatives as melanocortin-4 receptor agonists
US11/632,000 US7618987B2 (en) 2004-07-19 2005-07-15 Acylated piperidine derivatives as melanocortin 4-receptor agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58908904P 2004-07-19 2004-07-19
US60/589,089 2004-07-19

Publications (2)

Publication Number Publication Date
WO2006020277A2 WO2006020277A2 (en) 2006-02-23
WO2006020277A3 true WO2006020277A3 (en) 2006-07-20

Family

ID=35907993

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025505 WO2006020277A2 (en) 2004-07-19 2005-07-15 Acylated piperidine derivatives as melanocortin-4 receptor agonists

Country Status (9)

Country Link
US (1) US7618987B2 (en)
EP (1) EP1773338B1 (en)
JP (1) JP2008506779A (en)
CN (1) CN1988906A (en)
AT (1) ATE454148T1 (en)
AU (1) AU2005274701A1 (en)
CA (1) CA2574156A1 (en)
DE (1) DE602005018779D1 (en)
WO (1) WO2006020277A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
CN104974017B (en) * 2014-04-09 2017-11-17 上海医药工业研究院 The preparation method of (1R, 2S) 2 (3,4 difluorophenyl) cyclopropylamine D mandelates
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
PT3333165T (en) 2015-08-04 2019-10-29 Astellas Pharma Inc Piperazine derivative
JP6908041B2 (en) 2016-07-19 2021-07-21 アステラス製薬株式会社 Piperazine derivative
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713487B2 (en) * 2001-03-02 2004-03-30 Bristol-Myers Squibb Co. Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
US20040097546A1 (en) * 2001-02-28 2004-05-20 Goulet Mark T. Acylated piperidine derivatives as melanocortin-4 receptor agonists

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064002A1 (en) 1998-06-11 1999-12-16 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
CA2377369A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
IL150849A0 (en) 2000-02-11 2003-02-12 Vertex Pharma Piperzine and piperidine derivatives and pharmaceutical compositions containg the same
CA2403686C (en) 2000-03-23 2010-01-26 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2001070337A1 (en) 2000-03-23 2001-09-27 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU2001264977B2 (en) 2000-05-30 2005-04-14 Merck & Co., Inc. Melanocortin receptor agonists
AU2001288285B2 (en) 2000-08-23 2005-09-29 Merck & Co., Inc. Substituted piperidines as melanocortin receptor agonists
WO2002067869A2 (en) 2001-02-28 2002-09-06 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
KR20030076716A (en) 2001-02-28 2003-09-26 머크 앤드 캄파니 인코포레이티드 Acylated piperidine derivatives as melanocortin-4 receptor agonists
AU2002320494B2 (en) 2001-07-18 2006-06-29 Merck Sharp & Dohme Corp. Bridged piperidine derivatives as melanocortin receptor agonists
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
US7507753B2 (en) 2001-12-28 2009-03-24 Takeda Chemical Industries Ltd. Biaryl compound and use thereof
US20030195187A1 (en) 2002-02-04 2003-10-16 Chiron Corporation Guanidino compounds
AU2003216274A1 (en) 2002-02-11 2003-09-04 Neurocrine Biosciences, Inc. Pyrrole derivatives as ligands of melanocortin receptors
US20040010010A1 (en) 2002-04-30 2004-01-15 Ebetino Frank Hallock Melanocortin receptor ligands
JP2006505531A (en) 2002-09-11 2006-02-16 メルク　エンド　カムパニー　インコーポレーテッド Piperazine urea derivatives as melanocortin-4 receptor agonists
US7132539B2 (en) 2002-10-23 2006-11-07 The Procter & Gamble Company Melanocortin receptor ligands
US7160886B2 (en) 2003-03-03 2007-01-09 Merck & Co., Inc. Acylated piperazine derivatives as melanocortin-4 receptor agonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040097546A1 (en) * 2001-02-28 2004-05-20 Goulet Mark T. Acylated piperidine derivatives as melanocortin-4 receptor agonists
US6713487B2 (en) * 2001-03-02 2004-03-30 Bristol-Myers Squibb Co. Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same

Also Published As

Publication number Publication date
JP2008506779A (en) 2008-03-06
DE602005018779D1 (en) 2010-02-25
CN1988906A (en) 2007-06-27
AU2005274701A1 (en) 2006-02-23
ATE454148T1 (en) 2010-01-15
US7618987B2 (en) 2009-11-17
WO2006020277A2 (en) 2006-02-23
CA2574156A1 (en) 2006-02-23
EP1773338A2 (en) 2007-04-18
EP1773338B1 (en) 2010-01-06
EP1773338A4 (en) 2007-08-01
US20070191433A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
WO2004089307A8 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists
WO2002068388A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002068387A8 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2002067869A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
EP1610789A4 (en) Bicyclic piperidine derivatives as melanocortin-4 receptor agonists
TW200508223A (en) Acylated piperazine derivatives as melanocortin-4 receptor agonists
WO2005009950A3 (en) Piperidine derivatives as melanocortin-4 receptor agonists
EP1411940A4 (en) Bridged piperidine derivatives as melanocortin receptor agonists
WO2006020277A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2007041052A3 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2007041061A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
WO2008039418A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor modulators
WO2007047496A3 (en) Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
WO2006019787A3 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists
JO2351B1 (en) Acylated piperidine derivatives as melanocortin-4 receptor agonists

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 4796/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 11632000

Country of ref document: US

Ref document number: 2007191433

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2574156

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005274701

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200580024266.9

Country of ref document: CN

Ref document number: 2007522636

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005773009

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005274701

Country of ref document: AU

Date of ref document: 20050715

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005274701

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005773009

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11632000

Country of ref document: US